Loading...
01/10 16:00
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed performance: strong growth in school revenue and engineering gross profit, but declines in non-school revenue and life sciences gross profit. Margins are mixed, with some improvement but also declines. The Q&A highlights uncertainties, like visa issues for foreign candidates and persistent high medical costs. Despite optimistic long-term guidance, immediate concerns and lack of clear execution details temper positive sentiment. Without a market cap, a neutral prediction accounts for these balanced positives and negatives.
Consolidated Gross Profit $19.4 million for Q3 2025, an 8.8% increase over Q3 2024. The growth is attributed to strong performance in healthcare and engineering segments.
Adjusted EBITDA $5.5 million for Q3 2025, a slight decline of 1.4% compared to $5.6 million in Q3 2024. The decline is due to increased medical costs and administrative collection issues.
Adjusted EPS $0.42 for both Q3 2025 and Q3 2024, showing no year-over-year change.
Healthcare Gross Profit $9.0 million for Q3 2025, an 8.5% increase compared to $8.3 million in Q3 2024. Growth is driven by increased school revenue and higher billable hours in September and October.
Healthcare Gross Margin 30.0% for Q3 2025, compared to 31.2% in Q3 2024, reflecting a slight decline due to lower summer session revenue.
School Revenue $24.4 million for Q3 2025, a 20.7% increase compared to $20.2 million in Q3 2024. Growth is attributed to new school partnerships and expanded roles with existing clients.
Non-School Revenue $5.6 million for Q3 2025, an 11.3% decline compared to $6.4 million in Q3 2024, due to market competition.
Engineering Gross Profit $6.9 million for Q3 2025, a 17.3% increase compared to $5.9 million in Q3 2024. Growth is driven by record backlog and strong performance in energy services.
Engineering Gross Margin 22.0% for Q3 2025, compared to 24.4% in Q3 2024, reflecting a slight decline due to increased costs.
IT, Life Sciences, and Data Solutions Gross Profit $3.5 million for Q3 2025, a 4.2% decline compared to $3.7 million in Q3 2024. The decline is attributed to industry shifts and increased medical costs.
IT, Life Sciences, and Data Solutions Gross Margin 39.5% for Q3 2025, compared to 38.0% in Q3 2024, showing a slight improvement due to operational efficiencies.
Healthcare growth: Strong growth across the portfolio driven by quality, innovation, and client satisfaction. Expanded roster of new school partners and commitments from existing clients to broaden staffing roles.
Life Sciences AI integration: Partnered with an AI-driven company to streamline compliance protocols and reduce turnaround times. Created a dedicated life sciences engineering group to differentiate in the market.
Energy Services backlog: Secured record backlog for 2026, reinforcing leadership in modern grid infrastructure and advanced energy solutions.
Aerospace and Defense growth: Revenue grew 45%, gross profit by 49%, and EBITDA by 110% year-to-date compared to Q3 2024. Recognized as Bell Flight's Best New Supplier in 2025.
Healthcare market share: Increased market share in competitive K-12 markets, demonstrating trust and preference as a provider.
Energy Services market demand: Growing demand for modern grid infrastructure and energy solutions, with international project execution.
Aerospace and Defense market positioning: Increased demand across new clients and existing program support, with opportunities in secret and top-secret clearance projects.
Operational resilience: Despite $1.8 million in excess medical costs year-to-date, financial results remain resilient.
Hybrid resourcing model: Leveraged domestic expertise and global engineering design centers to address labor availability and resource bottlenecks.
AI and analytics in Life Sciences: Focused on predictive forecasting and real-time monitoring to optimize operations and fuel innovation.
Energy Services strategy: Integrated engineering and EPC model gaining momentum, solidifying position as a Tier 1 preferred partner.
Aerospace and Defense strategy: Investments in new service areas and expertise in supply chain manufacturing and quality engineering driving growth.
Excess Medical Costs: The company faced approximately $1.8 million in excess medical costs year-to-date, with Q3 being particularly impacted. This poses a financial strain on operations.
Competition in Healthcare Markets: Increased competition in certain healthcare markets could challenge market share and profitability, although the company has managed to grow its share so far.
Industry Shifts in Life Sciences: Tariffs, favored nation drug pricing, and process automation are causing momentum shifts, including workforce reductions among clients, which could impact demand for services.
Labor Availability and Resource Bottlenecks: Challenges in labor availability and resource bottlenecks in the engineering sector could hinder timely project execution and scalability.
Administrative Collection Issues: The company experienced administrative collection issues with two large school clients, negatively impacting cash flow from operations in Q3 2025.
Decline in Non-School Healthcare Revenue: Non-school healthcare revenue declined by 11.3% in Q3 2025 compared to Q3 2024, indicating potential challenges in diversifying revenue streams.
Healthcare: Strong growth expected in the 2025-2026 school year, driven by expanding partnerships with new and existing school clients. Anticipates benefits from a record foreign recruitment pipeline in 2026.
Life Sciences: Ongoing digital transformation and integration of AI-driven compliance expected to drive efficiency and enhance value proposition to pharma partners. Scaling of the new engineering group and expansion of managed service offerings will support growth.
Energy Services: Record backlog for 2026, with focus shifting to 2027 and beyond. Continued growth in substation modernization and energy resilient infrastructure projects. Leveraging hybrid resourcing model and digital tools to address labor and resource challenges.
Aerospace and Defense: Anticipates growth in 2026 with new opportunities in engineering, manufacturing, and supply chain areas. Programs are in early stages, with expectations to set a new baseline in 2026.
The selected topic was not discussed during the call.
The earnings call reveals mixed performance: strong growth in school revenue and engineering gross profit, but declines in non-school revenue and life sciences gross profit. Margins are mixed, with some improvement but also declines. The Q&A highlights uncertainties, like visa issues for foreign candidates and persistent high medical costs. Despite optimistic long-term guidance, immediate concerns and lack of clear execution details temper positive sentiment. Without a market cap, a neutral prediction accounts for these balanced positives and negatives.
The earnings call presented a mix of positive and negative elements. Revenue growth and strategic expansions are promising, particularly in engineering and healthcare sectors. Despite some revenue declines and delayed cash flows, the company maintains strong gross margins and cash flow recovery. The Q&A section revealed positive analyst sentiment towards strategic partnerships and market positioning. Although immigration challenges and lack of clear dividend plans pose risks, the overall outlook, including optimistic growth projections and strategic market positioning, suggests a positive stock price movement over the next two weeks.
The earnings call reveals strong financial performance with increased gross profit, EBITDA, and EPS. Positive growth in K-12 services and aerospace sectors, alongside reduced net debt and improved cash flow, indicate robust operational health. Despite some margin variability, guidance remains optimistic. The share repurchase plan further supports stock price appreciation. The Q&A section didn't reveal significant risks, supporting a positive outlook. However, lack of specific guidance and margin concerns temper expectations, placing the prediction in the 'Positive' range (2% to 8%).
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
